Robert A Wood, Alkis Togias, Scott H Sicherer, Wayne G Shreffler, Edwin H Kim, Stacie M Jones, Donald Y M Leung, Brian P Vickery, J Andrew Bird, Jonathan M Spergel, Ahmar Iqbal, Julie Olsson, Monica Ligueros-Saylan, Alkaz Uddin, Agustin Calatroni, Charmaine Marquis Huckabee, Nicole H Rogers, Nancy Yovetich, Jennifer Dantzer, Kim Mudd, Julie Wang, Marion Groetch, David Pyle, Corinne A Keet, Michael Kulis, Sayantani B Sindher, Andrew Long, Amy M Scurlock, Bruce J Lanser, Tricia Lee, Christopher Parrish, Terri Brown-Whitehorn, Amanda K Rudman Spergel, Maria Veri, Sanaz Daneshfar Hamrah, Erica Brittain, Julian Poyser, Lisa M Wheatley, R Sharon Chinthrajah
BACKGROUND: Food allergies are common and are associated with substantial morbidity; the only approved treatment is oral immunotherapy for peanut allergy. METHODS: In this trial, we assessed whether omalizumab, a monoclonal anti-IgE antibody, would be effective and safe as monotherapy in patients with multiple food allergies. Persons 1 to 55 years of age who were allergic to peanuts and at least two other trial-specified foods (cashew, milk, egg, walnut, wheat, and hazelnut) were screened...
February 25, 2024: New England Journal of Medicine